Management of Hexaconazole Poisoning in Pregnancy

Critical Considerations

• The American College of Obstetricians and Gynecologists and other medical guidelines suggest that high-dose azole exposure, including hexaconazole, during the first trimester carries teratogenic risk, including craniosynostosis, skeletal abnormalities, and characteristic facies 1, 2
• The FDA has warned that fluconazole at 400-800 mg/day during the first trimester is associated with birth defects, highlighting the need for cautious management of azole exposures in pregnancy 1, 2
• Azole teratogenicity risk is primarily confined to the first trimester, with effects occurring during early gestation, emphasizing the importance of early intervention and monitoring 1, 2
• Monitoring for maternal and fetal distress is crucial, particularly in the second and third trimesters, with aggressive maternal supportive care being the mainstay of treatment 3, 4
• The Centers for Disease Control and Prevention and other health organizations recommend that azole antifungals should not be administered as potential "antidotes" or treatments during pregnancy, especially during the first trimester, due to their potential harm to the fetus 1, 2, 5